Antipsychotic-like effects of the N-methyl-d-aspartate receptor modulator neboglamine: An immunohistochemical and behavioural study in the rat

Pharmacological Research

Volumn 61, Issue 5, 2010, Pages 430-436

  Chiusaroli, Riccardo ^a   Garofalo, Paolo ^a   Espinoza, Stefano ^a   Neri, Elisa ^a   Caselli, Gianfranco ^a   Lanza, Marco ^a  

^a Rotta Research Laboratorium   (Italy)

Author keywords

Antipsychotic agents; C Fos; Neboglamine (CR2249); NMDA receptors; Phencyclidine; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID; NEBOGLAMINE; NEUROTRANSMITTER; PHENCYCLIDINE; PROTEIN FOS; SERINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ACTIVITY; FOREBRAIN; FRONTAL CORTEX; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LOCOMOTION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SEPTUM NUCLEUS;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; HALOPERIDOL; IMMUNOHISTOCHEMISTRY; MALE; MOTOR ACTIVITY; PENTANOIC ACIDS; PHENCYCLIDINE; PROSENCEPHALON; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, WISTAR; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE; SERINE;

EID: 77950627538     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.12.010     Document Type: Article

References (42)

1. Tandon R., Fleischhacker W.W. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 2005, 79:145-155.
2. Ananth J., Parameswaran S., Hara B. Drug therapy in schizophrenia. Curr Pharm Des 2004, 10:2205-2217.
3. Trifirò G., Spina E., Gambassi G. Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile?. Pharmacol Res 2009, 59:1-12.
4. Baptista T., ElFakih Y., Uzcátegui E., Sandia I., Tálamo E., Araujo de Baptista E., et al. Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 2008, 22:477-495.
5. Iqbal M.M., Rahman A., Husain Z., Mahmud S.Z., Ryan W.G., Feldman J.M. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 2003, 15:33-48.
6. Deutch A.Y., Cameron D.S. Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience 1992, 46:49-56.
7. Nguyen T.V., Kosofsky B.E., Birnbaum R., Cohen B.M., Hyman S.E. Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci USA 1992, 89:4270-4274.
8. Robertson G.S., Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 1992, 46:315-328.
9. MacGibbon G.A., Lawlor P.A., Bravo R., Dragunow M. Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Mol Brain Res 1994, 23:21-32.
10. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994, 271:1058-1066.
11. Deutch A.Y., Duman R.S. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Neuroscience 1996, 70:377-389.
12. Ananth J., Burgoyne K.S., Gadasalli R., Aquino S. How do the atypical antipsychotics work?. J Psychiatry Neurosci 2001, 26:385-394.
13. Moghaddam B. Recent basic findings in support of excitatory amino acid hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1994, 18:859-870.
14. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999, 56:29-36.
15. Coyle J.T., Tsai G., Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci 2003, 1003:318-327.
16. Kinney G.G., Sur C., Burno M., Mallorga P.J., Williams J.B., Figueroa D.J., et al. The glycine transporter type-1 inhibitor N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J Neurosci 2003, 23:7586-7591.
17. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., et al. d-Serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005, 57:577-585.
18. Lane H.Y., Chang Y.C., Liu Y.C., Chiu C.C., Tsai G.E. Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 2005, 62:1196-1204.
19. Bowery N.G. Allosteric modulation of NMDA receptors: significance for therapeutics. Pharmacol Res 1990, 22:63.
20. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006, 26:365-384.
21. Labrie V., Lipina T., Roder J.C. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 2008, 200(October (2)):217-230.
22. Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999, 98(August (4)):427-436.
23. Shim S.S., Hammonds M.D., Kee B.S. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Arch Psychiatry Clin Neurosci 2008, 258:16-27.
24. Yang C.R., Svensson K.A. Allosteric modulation of NMDA receptor via elevation of brain glycine and d-serine: the therapeutic potentials for schizophrenia. Pharmacol Ther 2008, 120:317-332.
25. Garofalo P., Colombo S., Lanza M., Revel L., Makovec F. CR 2249: a new putative memory enhancer. Behavioural studies on learning and memory. J Pharm Pharmacol 1996, 48:1290-1297.
26. Lanza M., Bonnafous C., Colombo S., Revel L., Makovec F. Characterization of a novel putative cognition enhancer mediating facilitation of glycine effect on strychnine-resistant sites coupled to NMDA receptor complex. Neuropharmacology 1997, 36:1057-1064.
27. Pittaluga A., Vaccari D., Raiteri M. The " kynurenate test" , a biochemical assay for putative cognition enhancers. J Pharmacol Exp Ther 1997, 283:82-90.
28. Lanza M., Makovec F. Cognition enhancing profile of CR 2249, a new NMDA-glycine site modulator. CNS Drug Rev 1997, 3:245-259.
29. Pittaluga A., Pattarini R., Andrioli G.C., Viola C., Munari C., Raiteri M. Activity of putative cognition enhancers in kynurenate test performed with human neocortex slices. J Pharmacol Exp Ther 1999, 290:423-428.
30. Nilsson L.K., Linderholm K.R., Engberg G., Paulson L., Blennow K., Lindström L.H., et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res 2005, 80:315-322.
31. Erhardt S., Schwieler L., Nilsson L., Linderholm K., Engberg G. The kynurenic acid hypothesis of schizophrenia. Physiol Behav 2007, 92:203-209.
32. Ohmori T., Koyama T., Nakamura F., Wang P., Yamashita I. Effect of phencyclidine on spontaneous and N-methyl-d-aspartate (NMDA)-induced efflux of dopamine from superfused slices of rat striatum. Neuropharmacology 1992, 31:461-467.
33. Leveque J.-C., Macias W., Rajadhyaksha A., Carlson R.R., Barczak A., Kang S., et al. Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci 2000, 20:4011-4020.
34. Konradsson A., Marcus M.M., Hertel P., Svensson T.H., Jardemark K.E. Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex. Synapse 2006, 60:102-108.
35. Molteni R., Pasini M., Moraschi S., Gennarelli M., Drago F., Racagni G., et al. Reduced activation of intracellular signalling pathways in rat prefrontal cortex after chronic phencyclidine administration. Pharmacol Res 2008, 57:296-392.
36. Duncan G.E., Knapp D.J., Johnson K.B., Breese G.R. Functional classification of antidepressants based on antagonism of swim stress-induced fos-like immunoreactivity. J Pharmacol Exp Ther 1996, 277:1076-1089.
37. Swanson C.J., Schoepp D.D. A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists. Ann N Y Acad Sci 2003, 1003:309-317.
38. Chapman C.D., Gazzara R.A., Howard S.G. Effects of phencyclidine on extracellular levels of dopamine, dihydroxyphenylacetic acid and homovanillic acid in conscious and anesthetized rats. Neuropharmacology 1990, 29:319-325.
39. Contreras P.C. d-Serine antagonized phencyclidine- and MK-801-induced stereotyped behavior and ataxia. Neuropharmacology 1990, 29:291-293.
40. Tanii Y., Nishikawa T., Hashimoto A., Takahashi K. Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia in the rat. J Pharmacol Exp Ther 1994, 269:1040-1048.
41. Cartmell J., Monn J.A., Schoepp D.D. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 1999, 291:161-170.
42. Gozzi A., Herdon H., Schwarz A., Bertani S., Crestan V., Turrini G., et al. Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat. Psychopharmacology (Berl) 2008, 201:273-284.